Efficacy of Pilsicainide After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation

• Status: Unknown status
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Investigators hypothesized that the use of Pilsicainide after radiofrequency ablation of AF could reduce the incidence of recurrence of atrial arrhythmia during follow up compared with other class IC antiarrhythmic drugs.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Korea University
• Treatments: Anti-Arrhythmia Agents; Flecainide; Lidocaine; Pilsicainide; Polystyrene sulfonic acid; Propafenone

Criteria

Inclusion Criteria:

• patients with drug-refractory paroxysmal atrial fibrillation who requires catheter ablation

• patients who are aged 18-80 and agree with this study

Exclusion Criteria:

• patients who do not agree with this study

• patients with a history of catheter ablatio or surgery for atrial fibrillation

• patients who experienced side effects of pilsicainide before

• patients who has galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

• patients who has congestive heart failure with ejection fraction<40% or decompensated heart failure

• patients with significant coronary artery disease, liver/renal disease

• patients who has other kinds of arrhythmic which requires active treatment

• contraindication to warfarin therapy

• life expectancy <1 year]

• pregnancy